Pharmaceutical companies must screen and analyze published literature from the clinical development stage through post-marketing as part of their pharmacovigilance obligations. It is critical to detect safety signals as soon as possible to affect appropriate measures and protect patient safety. Medical literature is an important source of information and contributes to the detection of safety signals. The success of published literature surveillance is measured by precision and sensitivity.
PV Nugget #6 Literature Surveillance
Literature is regarded as a significant source of information in the monitoring of a medicinal product, its safety profile, and benefit-risk balance.…
Pharmacovigilance & Patient Safety
Clinical trial participants help us speed breakthroughs in modern drug development. Our job is to protect them.
Practical Implementation of Signal Detection in Iterative Benefit Risk Evaluation
This webcast with PRA Health Sciences' Jacinta Aniagolu-Johnson (Senior Director, Safety and Risk Management) explores how a well defined signal…